The Asia Pacific Cell Therapy Market would witness market growth of 28.6% CAGR during the forecast period (2020-2026).
The increasing number of clinical studies for cell-based therapies is boosting the growth of the market. This has brought considerable global funding in R&D and their clinical translation. The rising number of ongoing clinical trials is the result of the existence of government and private funding agencies that are consistently providing investments to promote projects across several phases of clinical trials.
In addition, the gradual advent of the latest technologies to encourage the growth of advanced therapies has fuelled the growth of the market. The arrival of proprietary cell lines is regarded as the main medium by which a product can be used for the manufacturing of a robust portfolio of candidates. For instance, Immunicum employs Chimeric Antigen Receptor T cell (CAR-T) expansion, T-cell primers, and dendritic cell neoantigen presentation technology to promote their product offerings for immuno-oncology.
Precision medicine can be considered as a new method for disease treatment and prevention, which considers individual variability in genes, environments, and lifestyles. Precision medicine includes the selection of drugs completely suitable to a patient on the basis of disease condition and history. Though this practice is expanding into all disease regions, oncology has witnessed the most development. Precision medicine provides a new pattern in oncology, where a patient gets personalized treatment. This method to disease diagnosis, treatment, prevention uses a global view of patients – from their genes and their environment to their lifestyles, like CAR-T therapy, are some of the major development.
The China market dominated the Asia Pacific Hospitals & Clinics Market by Country 2019, growing at a CAGR of 27.8 % during the forecast period. The Japan market is showcasing a CAGR of 29.5% during (2020 - 2026). Additionally, The India market is poised to grow at a CAGR of 31% during (2020 - 2026).
The Stem Cell market dominated the Malaysia Cell Therapy Market by Cell Type 2019, thereby, achieving a market value of $118.1 million by 2026. The Umbilical Cord-Derived market is estimated to grow at a CAGR of 32.7% during (2020 - 2026). The Adipose-Derived Stem Cell market is experiencing a CAGR of 34.1% during (2020 - 2026). Additionally, The Non-Stem Cell market is expected to witness a CAGR of 33.3% during (2020 - 2026).
Based on Therapy Type, the market is segmented into Autologous and Allogeneic. Based on Therapeutic Area, the market is segmented into Malignancies, Autoimmune Disorders, Musculoskeletal Disorders, Dermatology and Others. Based on End User, the market is segmented into Academic & Research Institutes and Hospitals & Clinics. Based on Cell Type, the market is segmented into Stem Cell, Umbilical Cord-Derived, Adipose-Derived Stem Cell, Non-Stem Cell, Bone Marrow, Blood and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fujifilm Holdings Corporation, Smith & Nephew PLC, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Medipost Co., Ltd., Stemedica Cell Technologies, Inc., NuVasive, Inc., Avantor, Inc., Vericel Corporation, and Pharmicell Co., Ltd.
Scope of the Study
Market Segments covered in the Report:
By Therapy Type
By Therapeutic Area
• Autoimmune Disorders
• Musculoskeletal Disorders
By End User
• Academic & Research Institutes
• Hospitals & Clinics
By Cell Type
• Stem Cell
• Umbilical Cord-Derived
• Adipose-Derived Stem Cell
• Non-Stem Cell
• Bone Marrow
• South Korea
• Rest of Asia Pacific
• Fujifilm Holdings Corporation
• Smith & Nephew PLC
• Kolon TissueGene, Inc.
• JCR Pharmaceuticals Co., Ltd.
• Medipost Co., Ltd.
• Stemedica Cell Technologies, Inc.
• NuVasive, Inc.
• Avantor, Inc.
• Vericel Corporation
• Pharmicell Co., Ltd.
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
Our reports have been used by over 10K customers, including:
The global single-use assemblies market is projected to reach USD 6.3 billion by 2026 from USD 2.2 billion in 2021, at a CAGR of 23.3% during the forecast period. The growth of the single-use assemblies market can primarily be attributed to the major advantages of single-use technologies as compared to traditional stainless-steel assemblies,...
“Axial spondyloarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route...
Global Cell Isolation Market By Product (Consumables and Instruments), By Cell Type (Human Cells and Animal Cells), By Source (Bone Marrow, Cord Blood/Embryonic Stem Cells, Adipose Tissue), By Technique (Centrifugation-Based Cell Isolation, Surface Marker-Based Cell Isolation, Filtration-Based Cell Isolation), By Application (Biomolecule...
306 pages •
By Global Industry Analysts
• May 2021
Global Cell Harvesting Market to Reach $359.2 Million by 2026
Cell harvesting is a next-generation technique that involves collection of stem cells from the culture media for R&D and therapeutic applications. Growth in the global market is spurred by of increasing investments...
The microcarrier market is majorly driven by factors such as rising demand for cell-based vaccines and therapeutics, the rapid growth of biologics and biosimilar industry, and increasing R&D and availability of funding for cell therapy research. Many of the current biologics in the pipeline are targeting the indications, which are small-molecule...
The Global Biologics CDMO Market was valued at USD 9.93 billion in 2020 and is expected to reach USD 18.63 billion by 2026, registering a CAGR of 10.87% during the forecast period (2021-2026). The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19 pandemic....
The global biologics safety testing market is projected to reach USD 6.2 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 12.4% during the forecast period. The growth of the global biologics safety testing market is driven by factors such as the growth in the biologics and biosimilars markets, growing concerns over cell culture contamination,...
The Formulation Development Outsourcing market was valued at approximately USD 8,055 million in 2020 and is expected to witness a revenue of USD 12,650 million in 2026, with a CAGR of 7.2% over the forecast period. The rapidly evolving threat of COVID-19 is impacting lives, communities, businesses, and industries around the world. The...
The global cell dissociation market size is projected to reach USD 561 million by 2026 from USD 282 million in 2021, at a CAGR of 14.7% during the forecast period. The growth in this market is attributed to the prevalence of cell based research, the increasing number of pharmaceutical and biotechnology companies. Moreover, the growth opportunities...
The biosimilar market reached a value of US$ 7.7 Billion in 2020. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost-saving initiatives from governments and third-party payers. Catalyzed by these factors, the market...
Chronic Disease Prevalence
Biosimilar Penetration Rate
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.